Related references
Note: Only part of the references are listed.A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
L. Tobalina et al.
ANNALS OF ONCOLOGY (2021)
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh T. Do et al.
CLINICAL CANCER RESEARCH (2021)
Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
Aruni Ghose et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
Shannon Neville Westin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).
Jung-Yun Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
Stephanie L. Wethington et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2020)
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
Jung-min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Stergios Boussios et al.
DRUGS IN R&D (2020)
Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)
K. Omatsu et al.
ANNALS OF ONCOLOGY (2020)
Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew et al.
ANNALS OF ONCOLOGY (2020)
Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial
J. A. Ledermann et al.
GYNECOLOGIC ONCOLOGY (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Jingyan Yi et al.
EBIOMEDICINE (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Exploiting DNA Replication Stress for Cancer Treatment
Tajinder Ubhi et al.
CANCER RESEARCH (2019)
Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
Lin Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Y Drew et al.
ANNALS OF ONCOLOGY (2019)
LBA1Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)
A González Martín et al.
ANNALS OF ONCOLOGY (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
Gabriel Balmus et al.
NATURE COMMUNICATIONS (2019)
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Jung-Min Lee et al.
LANCET ONCOLOGY (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
W. Y. Mansour et al.
SCIENTIFIC REPORTS (2018)
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca)
Joyce F. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)
J-M Lee et al.
ANNALS OF ONCOLOGY (2018)
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Renata Rodrigues da Cunha Colombo Bonadio et al.
CLINICS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Tamara B. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks
Huzefa Dungrawala et al.
MOLECULAR CELL (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Loss of PARP1 in human cancer cells confers resistance to PARP inhibition via activation of innate immune signaling
Rajib Ghosh et al.
CANCER RESEARCH (2017)
Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage
Joonyoung Her et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du et al.
NATURE MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair
Zeina Kais et al.
CELL REPORTS (2016)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
DNA-PK: A dynamic enzyme in a versatile DSB repair pathway
Anthony J. Davis et al.
DNA REPAIR (2014)
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
Qing Xia et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Role of 53BP1 in the Regulation of DNA Double-Strand Break Repair Pathway Choice
Arun Gupta et al.
RADIATION RESEARCH (2014)
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Jaeyoung J. Lim et al.
NEOPLASIA (2014)
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Richard Callaghan et al.
DRUG METABOLISM AND DISPOSITION (2014)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity
Julie K. Horton et al.
FRONTIERS IN ONCOLOGY (2013)
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Michael Fraser et al.
CLINICAL CANCER RESEARCH (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar et al.
CANCER RESEARCH (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson et al.
NATURE MEDICINE (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Negative Regulation of AKT Activation by BRCA1
Tao Xiang et al.
CANCER RESEARCH (2008)
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
Lao H. Saal et al.
NATURE GENETICS (2008)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs
RS Bindra et al.
CANCER RESEARCH (2005)
Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose) polymerase-1 inhibition in oxidative stress
A Tapodi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
RS Bindra et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Share Paper
